The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Histone H3.3K27M Represses p16 to Accelerate Gliomagenesis in a Murine Model of DIPG
Open accessPublished version of a preprint
Abstract
Abstract Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive pediatric brainstem tumor genetically distinguished from adult GBM by the high prevalence of the K27M mutation in the histone H3 variant H3.3 (H3F3A). This mutation reprograms the H3K27me3 epigenetic landscape of DIPG by inhibiting the H3K27-specific histone methyltransferase EZH2. This globally reduces H3K27me2/3, critical repressive marks responsible for cell fate decisions, and also causes focal gain of H3K27me3 throughout the epigenome. To date, the tumor-driving effects of H3.3K27M remain largely unknown. Here, it is demonstrated that H3.3K27M cooperates with PDGF-B in vivo, enhancing gliomagenesis and reducing survival of p53 wild-type (WT) and knockout murine models of DIPG. H3.3K27M expression drives increased proliferation of tumor-derived murine neurospheres, suggesting that cell-cycle deregulation contributes to increased malignancy in mutant tumors. RNA sequencing on tumor tissue from H3.3K27M-expressing mice indicated global upregulation of PRC2 target genes, and a subset of newly repressed genes enriched in regulators of development and cell proliferation. Strikingly, H3.3K27M induced targeted repression of the p16/ink4a (CDKN2A) locus, a critical regulator of the G0–G1 to S-phase transition. Increased levels of H3K27me3 were observed at the p16 promoter; however, pharmacologic reduction of methylation at this promoter did not rescue p16 expression. Although DNA methylation is also present at this promoter, it is not K27M dependent. Intriguingly, inhibition of DNA methylation restores p16 levels and is cytotoxic against murine tumor cells. Importantly, these data reveal that H3.3K27M-mediated p16 repression is an important mechanism underlying the proliferation of H3.3K27M tumor cells, as in vivo cdkn2a knockout eliminates the survival difference between H3.3K27M and H3.3WT tumor-bearing mice. Implications: This study shows that H3.3K27M mutation and PDGF signaling act in concert to accelerate gliomagenesis in a genetic mouse model and identifies repression of p16 tumor suppressor as a target of H3.3K27M, highlighting the G1–S cell-cycle transition as a promising therapeutic avenue. Mol Cancer Res; 15(9); 1243–54. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other attempts to model H3.3K27M-DIPG in vivo have required constitutive expression of the PDGF-B ligand, which is not present in pHGG and can induce tumors even with wild-type (WT) H3.3”
From H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas (2017) · cites this paper as Cordero et al., 2017
In the citing paper
“suggesting that, unlike WT PDGFRA, PDGFRAD842V does not require H3.3K27M to drive tumorigenesis in vivo”
From H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas (2017) · cites this paper as Cordero et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,951
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631
Lee, J., Kotliarova, S. E., Kotliarov, Y., Li, A., Su, Q., Donin, N. M., Pastorino, S., Purow, B. W., Christopher, N., Zhang, W., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.030 · Cited by 2,345
The Polycomb group protein EZH2 directly controls DNA methylation
Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.-M., et al. (2006) · Nature · doi:10.1038/nature04431 · Cited by 2,204
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D. T. W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.024 · Cited by 1,828
St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2012) · Nature Genetics · doi:10.1038/ng.1102 · Cited by 1,724
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Jacobs, J. J. L., Kieboom, K., Marino, S., DePinho, R. A., & van Lohuizen, M. (1999) · Nature · doi:10.1038/16476 · Cited by 1,580
Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma
Lewis, P. W., Müller, M. M., Koletsky, M. S., Cordero, F., Lin, S., Banaszynski, L. A., Garcia, B. A., Muir, T. W., Becher, O. J., & Allis, C. D. (2013) · Science · doi:10.1126/science.1232245 · Cited by 1,345
Self-citationSchlesinger, Y., Straussman, R., Keshet, I., Farkash, S., Hecht, M., Zimmerman, J., Eden, E., Yakhini, Z., Ben-Shushan, E., Reubinoff, B. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1950 · Cited by 1,226 · cited 1×
“H3K27me3 is known to recruit DNA methyltransferases (DNMT) to drive de novo DNA methylation in certain cancers, and the Cdkn2a locus can be regulated by both H3K27me3 and DNA methylation of promoter CpG islands (31, 43, 44).”
BackgroundEpigenetic stem cell signature in cancer
Widschwendter, M., Fiegl, H., Egle, D., Mueller-Holzner, E., Spizzo, G., Marth, C., Weisenberger, D. J., Campan, M., Young, J., Jacobs, I., et al. (2007) · Nature Genetics · doi:10.1038/ng1941 · Cited by 1,143
Ohm, J. E., McGarvey, K. M., Yu, X., Cheng, L., Schuebel, K. E., Cope, L., Mohammad, H. P., Chen, W., Daniel, V. C., Yu, W., et al. (2007) · Nature Genetics · doi:10.1038/ng1972 · Cited by 1,130
Wu, G., Li, Y., Qu, C., Chen, X. '., Edmonson, M. N., Ma, X., Nagahawatte, P., Hedlund, E., Rusch, M., Huether, R., et al. (2014) · Nature Genetics · doi:10.1038/ng.2938 · Cited by 1,126
Harbour, J. W., Luo, R. X., Santi, A. D., Postigo, A. A., & Dean, D. C. (1999) · Cell · doi:10.1016/s0092-8674(00)81519-6 · Cited by 1,057
Khuong-Quang, D.-A., Buczkowicz, P., Rakopoulos, P., Liu, X.-Y., Fontebasso, A. M., Bouffet, E., Bartels, U., Albrecht, S., Schwartzentruber, J., Letourneau, L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0998-0 · Cited by 1,028
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis
Sharpless, N. E., Bardeesy, N., Lee, K.-H., Carrasco, D., Castrillon, D. H., Aguirre, A. J., Wu, E. A., Horner, J. W., & DePinho, R. A. (2001) · Nature · doi:10.1038/35092592 · Cited by 848
Flicek, P., Amode, M. R., Barrell, D. G., Beal, K. M., Brent, S., Carvalho‐Silva, D., Clapham, P., Coates, G. M. P., Fairley, S., Fitzgerald, S. F., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr991 · Cited by 842
Bender, S., Tang, Y., Lindroth, A. M., Hovestadt, V., Jones, D. T. W., Kool, M., Zapatka, M., Northcott, P. A., Sturm, D., Wang, W., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.006 · Cited by 818
The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression
Chan, K.-M., Fang, D., Gan, H., Hashizume, R., Yu, C., Schroeder, M., Gupta, N., Mueller, S., James, C. D., Jenkins, R., et al. (2013) · Genes & Development · doi:10.1101/gad.217778.113 · Cited by 707
Self-citationFunctionally defined therapeutic targets in diffuse intrinsic pontine glioma
Grasso, C. S., Tang, Y., Truffaux, N., Berlow, N. E., Liu, L., Debily, M.-A., Quist, M. J., Davis, L. E., Huang, E. C., Woo, P. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3855 · Cited by 687
Castel, D., Philippe, C., Calmon, R., Dret, L. L., Truffaux, N., Boddaert, N., Pagès, M., Taylor, K. R., Saulnier, P., Lacroix, L., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1478-0 · Cited by 674
Paugh, B. S., Qu, C., Jones, C., Liu, Z., Adamowicz‐Brice, M., Zhang, J., Bax, D. A., Coyle, B., Barrow, J., Hargrave, D. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7252 · Cited by 672
Buczkowicz, P., Hoeman, C. M., Rakopoulos, P., Pajovic, S., Létourneau, L., Dzamba, M., Morrison, A., Lewis, P. W., Bouffet, É., Bartels, U. K., et al. (2014) · Nature Genetics · doi:10.1038/ng.2936 · Cited by 662
Self-citationTumour hypoxia causes DNA hypermethylation by reducing TET activity
Thienpont, B., Steinbacher, J., Zhao, H., D’Anna, F., Kuchnio, A., Ploumakis, A., Ghesquière, B., Van Dyck, L., Boeckx, B., Schoonjans, L., et al. (2016) · Nature · doi:10.1038/nature19081 · Cited by 635 · cited 1×
“Regulation of DNA methylation is complex but important to tumorigenesis, as recent evidence shows that hypoxia can induce loss of TET enzyme activity, which catalyzes DNA demethylation and therefore drives DNA hypermethylation in tumors (49).”
BackgroundDiffuse brainstem glioma in children: critical review of clinical trials
Hargrave, D. R., Bartels, U. K., & Bouffet, É. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70615-5 · Cited by 628
Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge
Sturm, D., Bender, S., Jones, D. T. W., Lichter, P., Grill, J., Becher, O., Hawkins, C., Majewski, J., Jones, C., Costello, J. F., et al. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3655 · Cited by 555
Self-citationKnutson, S. K., Kawano, S., Minoshima, Y., Warholic, N. M., Huang, K., Xiao, Y., Kadowaki, T., Uesugi, M., Kuznetsov, G., Kumar, N., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0773 · Cited by 547
Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma
Taylor, K. R., Mackay, A. G., Truffaux, N., Butterfield, Y. S. N., Morozova, O., Philippe, C., Castel, D., Grasso, C. S., Vinci, M., Carvalho, D. M., et al. (2014) · Nature Genetics · doi:10.1038/ng.2925 · Cited by 535
EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas
Mohammad, F., Weissmann, S., Leblanc, B., Pandey, D. P., Højfeldt, J. W., Comet, I., Zheng, C., Johansen, J. V., Rapin, N., Porse, B. T., et al. (2017) · Nature Medicine · doi:10.1038/nm.4293 · Cited by 535
Evidence for an instructive mechanism of de novo methylation in cancer cells
Keshet, I., Schlesinger, Y., Farkash, S., Rand, E., Hecht, M., Segal, E., Pikarsky, E., Young, R. A., Niveleau, A., Cedar, H., et al. (2006) · Nature Genetics · doi:10.1038/ng1719 · Cited by 483
Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2
Justin, N., Zhang, Y., Tarricone, C., Martin, S. R., Chen, S., Underwood, E., Marco, V. D., Haire, L. F., Walker, P. A., Reinberg, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms11316 · Cited by 427
Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2
Jiao, L., & Liu, X. (2015) · Science · doi:10.1126/science.aac4383 · Cited by 402
Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation
Funato, K., Major, T., Lewis, P. W., Allis, C. D., & Tabar, V. (2014) · Science · doi:10.1126/science.1253799 · Cited by 390
Gal‐Yam, E. N., Egger, G., Iniguez, L., Holster, H., Einarsson, S. O., Zhang, X., Lin, J., Liang, G., Jones, P. A., & Tanay, A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806437105 · Cited by 371
Flaherty, K. T., LoRusso, P. M., DeMichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O'Dwyer, P. J., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0509 · Cited by 366
Jackson, M., Krassowska, A., Gilbert, N., Chevassut, T. J. T., Forrester, L. M., Ansell, J., & Ramsahoye, B. H. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.20.8862-8871.2004 · Cited by 345
Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN
Bjerke, L. M., Mackay, A. G., Nandhabalan, M., Burford, A., Jury, A., Popov, S., Bax, D. A., Carvalho, D. M., Taylor, K. R., Vinci, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0426 · Cited by 333
Paugh, B. S., Broniscer, A., Qu, C., Miller, C. P., Zhang, J., Tatevossian, R., Olson, J. M., Geyer, J. R., Chi, S. N., da Silva, N. S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5677 · Cited by 328
Kotake, Y., Cao, R., Viatour, P., Sage, J., Zhang, Y., & Xiong, Y. (2007) · Genes & Development · doi:10.1101/gad.1499407 · Cited by 318
Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma
Monje, M., Mitra, S., Freret, M., Raveh, T., Kim, J., Masek, M., Attema, J., Li, G., Haddix, T., Edwards, M. S., et al. (2011) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1101657108 · Cited by 316
Puget, S., Philippe, C., Bax, D. A., Job, B., Varlet, P., Junier, M., Andreiuolo, F. D. M., Carvalho, D. M., Reis, R., Guerrini‐Rousseau, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030313 · Cited by 256
Poirier, J. T., Gardner, E. E., Connis, N., Moreira, A. L., de Stanchina, E., Hann, C. L., & Rudin, C. M. (2015) · Oncogene · doi:10.1038/onc.2015.38 · Cited by 249
Advances Toward an Understanding of Brainstem Gliomas
Donaldson, S. S., Laningham, F. H., & Fisher, P. G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6599 · Cited by 235
Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas
Paugh, B. S., Zhu, X., Qu, C., Endersby, R., Diaz, A. K., Zhang, J., Bax, D. A., Carvalho, D., Reis, R. M., Onar-Thomas, A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1491 · Cited by 235
Barton, K. L., Misuraca, K. L., Cordero, F. J., Dobrikova, E. Y., Min, H. D., Gromeier, M., Kirsch, D. G., & Becher, O. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077639 · Cited by 163
Self-citationBecher, O. J., Hambardzumyan, D., Walker, T. R., Helmy, K. Y., Nazarian, J., Albrecht, S., Hiner, R. L., Gall, S., Huse, J. T., Jabado, N., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2503 · Cited by 163
Self-citationErratum: Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
Grasso, C. S., Tang, Y., Truffaux, N., Berlow, N., Liu, L., Debily, M.-A., Quist, M. J., Davis, L. E., Huang, E., Woo, P. J., et al. (2015) · Nature Medicine · doi:10.1038/nm0715-827a · Cited by 132
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
Ozaki, A., Tanimoto, T., & Saji, S. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1510345 · Cited by 101
Hashizume, R., Smirnov, I. V., Liu, S., Phillips, J. J., Hyer, J. D., McKnight, T. R., Wendland, M. F., Prados, M. D., Banerjee, A., Nicolaides, T. P., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0973-6 · Cited by 94
Self-citationWiese, M., Schill, F., Sturm, D., Pfister, S. M., Hulleman, E., Johnsen, S. A., & Kramm, C. M. (2016) · Klinische Pädiatrie · doi:10.1055/s-0042-105292 · Cited by 61
von Werder, A., Seidler, B., Schmid, R. M., Schneider, G., & Saur, D. (2012) · Nature Protocols · doi:10.1038/nprot.2012.060 · Cited by 52
Misuraca, K. L., Barton, K. L., Chung, A., Diaz, A. K., Conway, S. J., Corcoran, D. L., Baker, S. J., & Becher, O. J. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0134-6 · Cited by 33
Self-citation
Cited by
Sorted by citations
Larson, J. D., Kasper, L. H., Paugh, B. S., Jin, H., Wu, G., Kwon, C.-H., Fan, Y., Shaw, T. I., Silveira, A. B., Qu, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.015 · Cited by 312
Pathania, M., De Jay, N., Maestro, N., Harutyunyan, A. S., Nitarska, J., Pahlavan, P., Henderson, S., Mikael, L. G., Richard-Londt, A., Zhang, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.014 · Cited by 264
Krug, B., Jay, N. D., Harutyunyan, A. S., Deshmukh, S., Marchione, D. M., Guilhamon, P., Bertrand, K. C., Mikael, L. G., McConechy, M. K., Chen, C. C. L., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.04.004 · Cited by 245
Liu, I., Jiang, L., Samuelsson, E. R., Salas, S. M., Beck, A., Hack, O. A., Jeong, D., Shaw, M. L., Englinger, B., LaBelle, J. J., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01236-3 · Cited by 225
PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism
Jain, S. U., Do, T. J., Lund, P. J., Rashoff, A. Q., Diehl, K. L., Cieslik, M. P., Bajic, A., Juretic, N., Deshmukh, S., Venneti, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09981-6 · Cited by 225
Metadata
- Authors
- Cordero, F. J., Huang, Z., Grenier, C., He, X., Hu, G., McLendon, R. E., Murphy, S. K., Hashizume, R., & Becher, O. J.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- Northwestern University (US)
- Corresponding author
- Becher, Oren J.
- Venue
- Molecular Cancer Research
- Published
- 2017-08-31
- Volume
- 15
- Issue
- 9
- Pages
- 1243-1254
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- PMC
- PMC5581686
- OpenAlex
- W2616008385
- Cited by
- 157
- References
- 56
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 8 · 2023: 15 · 2022: 25 · 2021: 28 · 2020: 24 · 2019: 21 · 2018: 10 · 2017: 3
- FWCI
- 9.11
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Molecular Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH (NS093986-01, NS086917)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- diffuse intrinsic pontine glioma, H3.3K27M mutation, histone H3.3, gliomagenesis, EZH2, H3K27me3, polycomb repressive complex 2, DNA methylation, cell proliferation, tumor cell survival, pediatric brainstem tumors
- MeSH terms
- Animals, Disease Models, Animal, Glioma, Histones, Mice, Inbred C57BL, Cyclin-Dependent Kinase Inhibitor p16, Brain Stem Neoplasms, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
